Trials / Withdrawn
WithdrawnNCT04280588
Fingolimod in COVID-19
Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- First Affiliated Hospital of Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of immune modulator together with ventilator support should be considered for the severe patients to prevent ARDS development. The sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology modulator which has been widely used in multiple sclerosis.The aim of this study was to determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fingolimod 0.5 mg | Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days |
Timeline
- Start date
- 2020-02-22
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2020-02-21
- Last updated
- 2020-11-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04280588. Inclusion in this directory is not an endorsement.